SharkNinja Indefinite-Lived Research and Development Assets decreased by 56.4% to $42.26M in Q4 2025 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates aggressive investment in external innovation, while a decrease may signal project completion, commercialization, or impairment charges.
This represents the value of acquired in-process research and development (IPR&D) projects that have not yet reached com...
Common in pharmaceutical and medical device sectors where M&A is a primary driver of R&D pipelines.
indefinite_lived_rd_assets| Q4 '24 | Q4 '25 | |
|---|---|---|
| Value | $96.81M | $42.26M |
| QoQ Change | — | -56.4% |
| YoY Change | — | -56.4% |